IV contrast administration for CT: A survey of practices for the screening prevention of contrast nephropathy

American Journal of Roentgenology

Volumn 186, Issue 6, 2006, Pages 1651-1658

  Elicker, Brett M ^a,d   Cypel, Yasmin S ^b,c   Weinreb, Jeffrey C ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b American College of Radiology   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast media; Contrast nephropathy; CT; Radiology practice; Renal disease; Screening

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; FENOLDOPAM; GADOLINIUM CHELATE; IODINATED CONTRAST MEDIUM; IODIXANOL; IODINE DERIVATIVE;

ACUTE ABDOMEN; AORTA DISSECTION; ARTICLE; CANCER STAGING; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST NEPHROPATHY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LUNG EMBOLISM; MULTIPLE MYELOMA; NEPHROTOXICITY; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOLOGIST; AGE; CHEMICALLY INDUCED DISORDER; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; RISK FACTOR;

AGE FACTORS; CONTRAST MEDIA; DATA COLLECTION; HUMANS; INJECTIONS, INTRAVENOUS; IODINE COMPOUNDS; KIDNEY DISEASES; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33745488012     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.05.0407     Document Type: Article

References (35)

1. Morcos SK, Thomsen HS, Webb JAW. Contrast Media Safety Committee of the European Society of Urogenital Radiology. Contrast-media induced nephrotoxicity: a consensus report. Eur Radiol 1999; 9:1602-1613
2. D'Elia JA, Gleanson RE, Alday M, et al. Nephrotoxicity from angiographic contrast material: a prospective study. Am J Med 1982; 72:719-725
3. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74:243-248
4. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39:930-936
5. Manske C, Sprafka J, Strong J, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89:615-620
6. McCollough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368-375
7. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264
8. American College of Radiology. Manual on contrast media, ed. 4.1. Reston, VA: American College of Radiology, 2003:15-18
9. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86:649-652
10. Lautin EM, Freeman NJ, Shoenfeld AH, et al. Radiocontiast-associated renal dysfunction: incidence and risk factors. AJR 1991; 157:49-58
11. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995; 47:254-261
12. Teruel JL, Marcen R, Onaindia JM, Serrano A, Quereda C, Ortuno J. Renal function impairment caused by intravenous urography: a prospective study. Arch Intern Med 1981; 141:1271-1274
13. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183:519-521
14. Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989; 36:730-740
15. Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5:125-137
16. Parfey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989; 320:143-149
17. Barrett BJ, Parfrey PS, Vavasour RH, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992; 41:1274-1279
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41
19. Campens D, Buntinx F. Selecting the best renal function tests: ameta-analysis of diagnostic studies. Int J Technol Assess Health Care 1997; 13:343-356
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130:461-470
21. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant 2001; 16:1042-1046
22. Olsen JC, Salomon B. Utility of the creatinine prior to intravenous contrast studies in the emergency department. J Emerg Med 1996; 14:543-546
23. Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT examinations? Radiology 2000; 216:481-484
24. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med 1989; 110:119-124
25. Moreau JF, Kreis H, Barbanel CL, Michel JR. Effects of iodine contrast media on function of the human transplanted kidneys [in French]. Nouv Presse Med 1975; 4:2643-2646
26. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clin Nephrol 2000; 54:11-14
27. DeFronzo RA, Humphrey RL, Wright JR, Cooke CR. Acute renal failure in multiple myeloma. Medicine 1975; 54:209-223
28. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002; 57:279-283
29. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362:598-603
30. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290:2284-2291
31. Thomsen HS, Almen T, Morcos SK, members of Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 2002; 12:2600-2605
32. Elmstahl B, Leander P, Nyman U, Chai C-M, Almen T, Frennby B. Nephrotoxicity after renal angiography using iodine and gadolinium contrast media in pigs with renal damage. Acad Radiol 2002; 9[suppl 2]:S531-S534
33. Rieger J, Sitter T, Toepfer M, Linsenmaier U, Pfeifer KJ, Schiffl H. Gadolinium as an alternative contrast a gent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 2002; 17:824-828
34. Erley CM, Bader BD, Berger ED, et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotemic patients. Nephrol Dial Transplant 2004; 19:2526-2531
35. Schuster ME, Fishman JE, Copeland JF, Hatabu H, Boiselle PM. Pulmonary embolism in pregnant patients: a survey of practices and policies for CT pulmonary angiography. AJR 2003; 181:1495-1498